Specifica, a Q2 Solutions Company, develops and delivers exceptional antibody libraries to support drug discovery. Our patented Generation 3 platform yields drug-like antibodies directly from selections, minimizing the need for downstream affinity and biophysical engineering.
Specifica provides high affinity antibodies with excellent developability and high diversity, saving time and money during development.
In examining two-group differential analysis, it is apparent that different statistical methods can yield very different results even given the same RNA-Seq input data. In particular, we have...
With more than 25 years of experience, Rules-Based Medicine, a Q2 Solutions company develops, validates and manufactures its assays with integrity and commitment for the most reliable, reproducible...
By Chloe Ackaert, Jana Schockaert, Aurelie Mazy, Martijn Vlaming, and Sofie PattynPresented at the American Association for Cancer Research (AACR) Annual Meeting, April 5-10, 2024 Bispecifics...